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                                      The human   ARID4A   and   ARID4B   genes, previously known as 
retinoblastoma-binding protein 1 (  RBBP1  ,   RBP1  ) (  1  ,  2  ) and   RBBP1    –
  like protein 1 (  RBBP1L1  ) (  3  ), respectively, are homologous members 
of the AT-rich interaction domain (  ARID  ) gene family (  4  ). The 
ARID4A amino acid sequence, but not that of ARID4B, contains an 
LVCHE sequence as a conserved LXCXE motif known to interact 
with the pocket of retinoblastoma protein (RB) (  1  ,  2  ). We reported 
that ARID4A interacts with ARID4B (  5  ). Both ARID4A and ARID4B 
contain a Tudor domain, an ARID domain, and a chromodomain (  4  ), 
as well as two repression domains, R1 and R2, with part of the R1 
domain overlapping the ARID domain (  6  ). The ARID domain con-
tains a helix-turn-helix structure with DNA binding activity (  7  ). 
Chromodomains are found in a variety of proteins that play roles in 
the functional organization of chromosome structure through chro-
matin remodeling (  8    –    10  ). Both chromodomains and Tudor domains 
mediate binding to methylated lysines of histones H3 and H4 (  11    –    14  ). 
ARID4A recruited by RB has been defined as a repressor of E2F-
dependent transcription (  15  ). Through their R2 regions, ARID4A 
and ARID4B serve as adapters to recruit the mSin3A  –  histone deac-
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     Background     Leukemia evolves through a multistep process from premalignancy to malignancy. Epigenetic alterations, 
including histone modifications, have been proposed to play an important role in tumorigenesis. The 
involvement of two chromatin remodeling genes, retinoblastoma-binding protein 1 (  Rbbp1  /  Arid4a  ) and 
  Rbbp1  -like 1 (  Rbbp1l1  /  Arid4b  ), in leukemogenesis was not characterized.   
     Methods     The leukemic phenotype of mice deficient for   Arid4a   with or without haploinsufficiency for   Arid4b   was 
investigated by serially monitoring complete blood counts together with microscopic histologic analysis 
and flow cytometric analysis of bone marrow and spleen from the   Arid4a   
     /       mice or   Arid4a         /        Arid4b         /       
mice. Regulation in bone marrow cells of downstream genes important for normal hematopoiesis was 
analyzed by reverse transcription  –  polymerase chain reaction. Genotypic effects on histone modifications 
were examined by western blotting and immunofluorescence analysis. All statistical tests were two-sided.   
     Results     Young (2  –  5 months old)   Arid4a  -deficient mice had ineffective blood cell production in all hematopoietic 
lineages. Beyond 5 months of age, the   Arid4a   
       /         mice manifested monocytosis, accompanied by severe 
anemia and thrombocytopenia. These sick   Arid4a   
       /         mice showed bone marrow failure with myelofibrosis 
associated with splenomegaly and hepatomegaly. Five of 42   Arid4a   
     /       mice and 10 of 12   Arid4a         /        Arid4b         /       mice 
progressed to acute myeloid leukemia (AML) and had rapid further increases of leukocyte counts. 
Expression of   Hox   genes (  Hoxb3  ,   Hoxb5  ,   Hoxb6  , and   Hoxb8  ) was decreased in   Arid4a  -deficient bone mar-
row cells with or without   Arid4b   haploinsufficiency, and   FoxP3   expression was reduced in   Arid4a   
     /        Arid4b         /       
bone marrow. Increases of histone trimethylation of H3K4, H3K9, and H4K20 (fold increases in trimethyl-
ation = 32, 95% confidence interval [CI] = 27 to 32; 45, 95% CI = 41 to 49; and 2.2, 95% CI = 1.7 to 2.7, 
respectively) were observed in the bone marrow of   Arid4a  -deficient mice.   
     Conclusions       Arid4a  -deficient mice initially display ineffective hematopoiesis, followed by transition to chronic myelo-
monocytic leukemia (CMML)  –  like myelodysplastic/myeloproliferative disorder, and then transformation to 
AML. The disease processes in the   Arid4a  -deficient mice are very similar to the course of events in 
humans with CMML and AML. This mouse model has the potential to furnish additional insights into the 
role of epigenetic alterations in leukemogenesis, and it may be useful in developing novel pharmacological 
approaches to treatment of preleukemic and leukemic states.   
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etylase (HDAC) histone-modifying complex to E2F-dependent 
promoters (  6  ,  16  ,  17  ). ARID4A and ARID4B also provide a repressive 
function in an HDAC-independent manner through their R1 regions. 
Transcriptional repression activity via the R1 region is controlled by 
SUMOylation, a posttranslational modification by small ubiquitin-
related modifier proteins (  18  ). 
  Several lines of evidence suggest that ARID4A and ARID4B may 
be involved in the pathogenesis of breast and other cancers. RB (with 
which ARID4A interacts and which is inactivated in many tumors) 
has been shown to be involved in many cellular processes, including 
control of the cell cycle, cell differentiation, DNA-damage responses, 
DNA replication, and protection against apoptosis (  19  ). Repression 
of E2F-dependent transcription by ARID4A and ARID4B in con-
junction with RB leads to cell arrest reminiscent of senescence 
(  15  ,  18  ). Screening a cDNA library from the MCF7 breast cancer 
cell line with IgG puriﬁ  ed from the serum of a breast cancer patient 
identiﬁ  ed ARID4A and ARID4B as tumor-associated antigens, and 
breast cancer patients have high titers of antibodies against both 
proteins (  3  ,  20  ,  21  ). Furthermore, human cytotoxic T cells stimulated 
with ARID4A peptides kill breast cancer cells (  22  ). ARID4A also 
interacts with the breast cancer metastasis suppressor 1 (BRMS1) and 
the BRMS1 homologue p40 in the mSin3  –  HDAC complex (  23  ,  24  ). 
BRMS1 reduces the metastatic activity of cancer cells without affect-
ing tumorigenicity (  25  ). Despite these reports, the role of ARID4A 
and ARID4B in cancer development is unclear. 
  Preleukemic conditions are relatively common in aging popula-
tions, and little is known about their pathogenesis or how they 
predispose to leukemia. Many physicians and patients face this 
distressing clinical situation on a chronic basis, and there is little 
that the physician can offer to prevent the potential transformation 
to malignancy because the mechanisms by which cancer progresses 
from premalignancy to malignancy are not fully understood.
    Epigenetic alterations such as histone modiﬁ  cations of chroma-
tin structure have been suggested to be involved in the develop-
ment of leukemia and other cancers (  26  ). Although an increasing 
number of chromatin remodeling proteins have been deﬁ  ned bio-
chemically (  27  ), their biological functions, particularly in the 
context of an animal model, are poorly characterized, and the 
molecular events governing chromatin reorganization in cancer 
cells remain relatively unexplored. Recently, we developed mouse 
models for   Arid4a   and   Arid4b   deﬁ  ciency that demonstrated the 
function of   Arid4a   and   Arid4b   in the regulation of genomic 
imprinting through control of epigenetic modiﬁ  cations (  5  ). Here, 
we use these mouse models deﬁ  cient for   Arid4a  , alone or in com-
bination with haploinsufﬁ  ciency for   Arid4b  , to analyze a premalig-
nant hematopoietic disorder and eventual leukemia.
      Methods 
    Animal Care 
  The mice (100 wild-type mice, 150   Arid4a         /       mice, 40   Arid4a   
     /     
  Arid4b         /       mice, and 40   Arid4a
         /        Arid4b   
     /       mice) were all bred and 
maintained according to a protocol approved by the Baylor College 
of Medicine Animal Care and Use Committee at the institution’s 
specific pathogen  –  free mouse facility, which is approved by the 
American Association for Accreditation of Laboratory Animal Care 
and is operated in accordance with current regulations and stan-
dards of the US Depart  ments of Agriculture and of Health and 
Human Services. 
  Beginning at 5 months of age, the   Arid4a         /       mice and   
Arid4a         /        Arid4b   
     /       mice were monitored weekly for signs of mor-
bidity. Blood was obtained weekly for complete blood cell counts. 
Mice were sacriﬁ  ced when they met any of the following criteria: 
1) obvious morbidity, in which case mice proved to have either 
severe anemia or greatly increased white blood cell (WBC) counts; 
2) severe anemia or high WBC counts with milder or impending 
morbidity; or 3) marked splenomegaly or hepatomegaly. Mice 
were anesthetized with isoﬂ   urane and then killed by 
cervical dislocation. The mice were dissected, and organs were 
examined for the presence or absence of tumor enlargement. The 
lung, spleen, and liver were removed, and bone marrow cells from 
both femurs were ﬂ  ushed with syringes.   
    Hematologic Analysis 
  Mice (52 wild-type mice, 50   Arid4a         /       mice, 40   Arid4a   
     /        Arid4b   
     /       
mice, and 10   Arid4a         /        Arid4b   
     /       mice) were anesthetized with 
isoflurane, and blood from each mouse was obtained from the 
retro-orbital venous plexus. Complete blood cell counts were 
determined with an analyzer (ADVIA 120 Hematology System; 
Bayer Diagnostics). 
  Peripheral blood and bone marrow smears were stained with 
Wright  –  Giemsa stain. On the peripheral blood smears (from 10 
wild-type mice, more than 20 chronic myelomonocytic leukemia 
[CMML]  –  like   Arid4a         /       mice, three acute myeloid leukemia 
[AML]   Arid4a         /       mice, and ﬁ  ve AML   Arid4a   
     /        Arid4b   
     /       mice) and 
    CONTEXT AND CAVEATS 
    Prior knowledge 
  Epigenetic modifications of DNA have been proposed to play an 
important role in carcinogenesis. The involvement of two chroma-
tin remodeling genes,   Arid4a   and   Arid4b  , in the etiology of leuke-
mia was unknown.   
    Study design 
  Mice deleted for   Arid4a   or mice deleted for   Arid4a   and haploinsuffi-
cient for   Arid4b   were characterized in terms of blood counts, bone 
marrow abnormalities as revealed by histologic analysis, gene tran-
scription, and epigenetic modification in their bone marrow cells.   
    Contribution 
  The fact that the genetically modified mice progressed to acute 
myeloid leukemia suggests a critical role for epigenetic modi-
fications mediated by   Arid4a and Arid4a   in suppression of 
leukemogenesis.   
    Implications 
  The mouse model described here may be useful for studying the 
etiology of leukemia and the role that epigenetic modification plays 
in this process.   
    Limitations 
  The suitability of the mouse strains described here as a model for 
human leukemia and the precise roles of   Arid4a   and   Arid4b   in 
chromatin remodeling remain to be determined. 
    From the Editors       
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bone marrow smears (from ﬁ  ve wild-type mice, ﬁ  ve CMML-like 
  Arid4a         /       mice, two AML  Arid4a   
     /       mice, and three AML   Arid4a   
     /       
Arid4b         /       mice), we analyzed blasts, immature precursors, WBCs 
(including lymphocytes, neutrophils, monocytes, eosinophils, and 
basophils), red blood cells (RBCs), and platelets.   
    Histologic Analysis 
  For bone marrow examination, femurs from three wild-type mice 
and three   Arid4a         /       mice were fixed and decalcified by immersion 
in Cal-EXII solution (Fisher Scientific, Pittsburgh, PA). Spleen and 
liver from five wild-type mice, five CMML-like mice, and five 
AML mice were fixed in 10% formalin (Fisher Scientific). Histology 
was performed on 5-  µ  m paraffin-embedded tissue sections that 
were stained either with reticulin to show myelofibrosis for femur 
bone sections (three slides from three wild-type mice and three 
slides from three   Arid4a         /       mice) or with hematoxylin and eosin to 
show extramedullary hematopoiesis in spleen and liver (one slide 
each from five wild-type mice, five CMML-like   Arid4a         /       mice, and 
five AML   Arid4a         /        Arid4b   
     /       mice).   
    Flow Cytometry 
  Spleens were removed from mice and dissociated into single 
cells by sliding tissue between two superfrost microscope slides. 
RBCs were lysed by hypotonic buffer (NH  4  Cl, 0.14 M; Tris, 0.017 
M, pH 7.2). Cells from spleen or bone marrow were gently filtered 
through 70-  µ  m cell strainers (BD Falcon, VWR, Batavia, IL) 
and were stained with directly fluorescein-5-isothiocyanate (FitC)-
conjugated antibodies to c-kit (2B8, eBioscience, San Diego, CA), 
Sca1 (D7, eBioscience), Mac1 (M1/70, BD Biosciences Pharmingen, 
San Jose, CA), Gr1 (RB6-8C5, BD Biosciences Pharmingen), B220 
(RA3-6B2, BD Biosciences Pharmingen), CD19 (1D3, BD 
Biosciences Pharmingen), CD3 (145-2C11, BD Biosciences 
Pharmingen), or Ter119 (Ter119, eBioscience). A lineage antibody 
cocktail (Lin) included antibodies against Mac1 (M1/70), Gr1 
(RB6-8C5), CD4 (L3T4, BD Biosciences Pharmingen), CD8 
(53-6.7, BD Biosciences Pharmingen), CD19 (1D3), and B220 
(RA3-6B2) to stain bone marrow cells. All antibodies were diluted 
(1:100) in phosphate-buffered saline (PBS). Hematopoietic stem 
cells (HSCs) (Lin        Sca1 
      c-Kit 
      ), common myeloid progenitors 
(CMPs) (Lin        Sca1 
      c-Kit 
      ), granulocytes and monocytes 
(Gr1        Mac1 
      ), erythroid cells (Ter119 
      ), T cells (CD3 
      ), and B cells 
(B220        CD19 
      ) were analyzed. For apoptosis analysis, bone marrow 
cells were stained with annexin V –  FITC conjugates (BD Biosciences 
Pharmingen). Cells were then washed and analyzed by flow cytom-
etry (Beckman-Coulter EPICS XL-MCL).   
    Immunofluorescence 
  Bone marrow cells flushed from femur bones were fixed in 4% 
paraformaldehyde, spread on glass slides, and permeabilized in cold 
acetone. Subsequently, cells were blocked with 5% bovine serum 
albumin in PBS, followed by incubation with primary antibodies 
against trimethylated H3K9, H3K4, or H4K20 (07-442 for 
H3K9me3, 05-745 for H3K4me3, and 07-463 for H4K20me3, 
Upstate, Charlottesville, VA) at a dilution of 1:200 in blocking solu-
tion. Then, cells were washed with blocking solution and incubated 
with Alexa 488  –  conjugated goat anti  –  rabbit secondary antibody 
(Molecular Probes, Invitrogen, Carlsbad, CA). Cells were mounted 
with Vectashield containing 4’,6-diamidino-2-phenylindole (DAPI) 
(Vector Laboratories, Burlingame, CA) and analyzed on a deconvo-
lution fluorescence microscope (DeltaVision Restoration 
Microscope, Zeiss, Jena, Germany).   
    Western Blotting 
  Bone marrow cells flushed from femurs were resuspended in lysis 
buffer (10 mM HEPES, pH 7.9, 1.5 mM MgCl  2  , 10 mM KCl, and 
protease inhibitors [Complete protease inhibitor cocktail tablets, 
Roche, Indianapolis, IN]). Histones were acid extracted by 0.2 N 
HCl and precipitated with 20% trichloroacetic acid. Proteins were 
electrophoresed on 7.5% Tris  –  Cl ready gels (Bio-Rad, Hercules, 
CA) and then transferred to nitrocellulose membranes (Bio-Rad). 
The incubations with the appropriate primary antibodies were per-
formed as follows: rabbit anti-H3 (1:1000 dilution, ab1791, Abcam, 
Cambridge, MA), goat anti-H4 (1:100 dilution, sc-8658, Santa Cruz 
Biotechology, Santa Cruz, CA), rabbit anti-H2AX (1:5000 dilution, 
BL179, Bethyl, TX), rabbit anti-H3K4me3 (1:4000 dilution, 05-
745, Upstate), rabbit anti-H3K9me3 (1:500 dilution, 07-523, 
Upstate), or rabbit anti-H4K20me3 (1:200 dilution, 07-749, 
Upstate). The membranes were then incubated with either goat 
anti  –  rabbit IgG horseradish peroxidase (HRP) (1:5000 dilution, ac-
2004, Santa Cruz Biotechnology) or donkey anti  –  goat HRP (1:5,000 
dilution, ac-2020, Santa Cruz Biotechnology). Antibody binding was 
detected by enhanced chemiluminesence (ECL, Amersham, 
Piscataway, NJ).   
    Reverse Transcription  –  Polymerase Chain Reaction 
  Total RNA was purified from bone marrow cells using an RNeasy 
plus kit (Qiagen, Hilden, Germany). Total RNA (5   µ  g) was used 
for reverse transcription to synthesize the first-strand cDNA 
(Superscript III First-strand synthesis system, Invitrogen). cDNA 
(5   µ  g) was used for polymerase chain reaction (PCR). PCR condi-
tions and primer sequences have been described (28) and/or are 
listed in Supplementary Table 1, available online. Hprt transcripts 
were amplified as a control for gene expression.   
    Statistical Analysis 
  Means and the accompanying 95% confidence intervals were calcu-
lated from at least three independent experiments. Group means 
were compared using a two-sided Student   t   test.   P   values less than 
.05 were considered to be statistically significant.     
    Results 
    A CMML-like Myelodysplastic/Myeloproliferative       
Disorder in   Arid4a  -Deficient Mice 
  To investigate the function of   Arid4a   and   Arid4b  , we bred   Arid4a   
null (  Arid4a           /        ) mice and mice null for   Arid4a   and heterozygous for 
the   Arid4b   deletion (  Arid4a           /          Arid4b   
     /      ); homozygous null mutants 
for   Arid4b   (both   Arid4a   
 
 
/      Arid4b   
     /       and   Arid4a   
       /          Arid4b   
     /      ) were 
not viable and died before E7.5 (  5  ). Young (2  –  5 months old) adult 
  Arid4a  -deficient mice initially had ineffective blood cell production 
in all hematopoietic lineages, with mild leukopenia (WBC: mean 
wild-type count = 7.64 × 10  6  /mL, mean   Arid4a   
     /       count = 4.09 × 
10  6  /mL, difference = 3.55 × 10 
6  /mL, 95% confidence interval [CI] = 
2.72 × 10  6  /mL to 4.38 × 10 
6  /mL,   P   < .001. Lymphocyte: mean 1250   Articles | JNCI  Vol. 100, Issue 17  |  September 3, 2008
wild-type count = 6.29 × 10 
6  /mL, mean   Arid4a   
     /       count = 3.21 × 
10  6  /mL, difference = 3.08 × 10 
6  /mL, 95% CI = 2.22 × 10 
6  /mL to 
3.94 × 10  6  /mL,   P   < .001. Neutrophil: mean wild-type count = 0.84 × 
10  6  /mL, mean   Arid4a   
     /       count = 0.51 × 10 
6  /mL, difference = 0.33 × 
10  6  /mL, 95% CI = 0.16 × 10 
6  /mL to 0.51 × 10 
6  /mL,   P   = .043) and 
mild anemia (RBC: mean wild-type count = 8.96 × 10  9  /mL, mean 
  Arid4a         /       count = 7.88 × 10 
9  /mL, difference = 1.08 × 10 
9  /mL, 95% 
CI = 0.5 × 10  9  /mL to 1.66 × 10 
9  /mL,   P   = .017; hemoglobin: mean 
wild-type count = 137.8 g/L, mean   Arid4a         /       count = 125.0 g/L, dif-
ference = 12.8 g/L, 95% CI = 5.0 g/L to 20.7 g/L,   P   = .035) with 
statistically significant thrombocytopenia (platelet: mean wild-type 
count = 1144.3 × 10  6  /mL, mean   Arid4a   
     /       count = 225.8 × 10 
6  /mL, 
difference = 918.5 × 10  6  /mL, 95% CI = 802.3 × 10 
6  /mL to 1034.7 × 
10  6  /mL,   P   < .001) (  Figure 1, A  ). Beyond 5 months of age, the 
  Arid4a           /         mice manifested monocytosis (monocyte: mean wild-type 
count = 0.2 × 10  6  /mL, mean   Arid4a   
     /       count = 0.9 × 10 
6  /mL, differ-
ence = 0.7 × 10  6  /mL, 95% CI = 0.55 × 10 
6  /mL to 0.85 × 10 
6  /mL,   
P   < .001), accompanied with severe anemia (RBC: mean wild-type 
count = 8.6 × 10  9  /mL, mean   Arid4a   
     /       count = 3.1 × 10 
9  /mL, differ-
ence = 5.5 × 10  9  /mL, 95% CI = 5.0 × 10 
9  /mL to 6.0 × 10 
9  /mL,   P   < 
.001; hemoglobin: mean wild-type count = 130 g/L, mean   Arid4a         /       
count = 48 g/L, difference = 82 g/L, 95% CI = 76 g/L to 88 g/L, 
  P   < .001) and severe thrombocytopenia (platelet: mean wild-type 
count = 1169 × 10  6  /mL, mean   Arid4a   
     /       count = 76 × 10 
6  /mL, dif-
ference = 1093 × 10  6  /mL, 95% CI = 1036 × 10 
6  /mL to 1150 × 10 
6  /
mL,   P   < .001) (  Figure 1, A  ). Peripheral blood smears from older 
(more than 5 months old) sickly   Arid4a           /         mice showed the presence 
of teardrop poikilocytes (  Figure 1, B, a  ) and increased numbers of 
immature erythroid cells (  Figure 1, B, b and c  ). Immature and 
maturing mononuclear cells morphologically consistent with the 
monocyte lineage were also noted in the peripheral blood (  Figure 1, 
B, d  ). Some monocytoid cells that contained phagocytosed RBCs 
were also present (  Figure 1, B, e  ). The   Arid4a           /         mice showed signs 
of morbidity (eg, ruffled hair, decreased activity, and rapid respira-
tion). Mortality of the   Arid4a           /         mice increased sharply from 
6 months of age onward, with no   Arid4a           /         mice surviving past 
22 months of age (  Figure 1, C  ). Increased mortality appeared to be 
associated with increasing severity of the hematologic abnormalities, 
especially severe anemia, in   Arid4a           /         mice.         
  Bone marrow from sick   Arid4a           /         mice developing monocytosis 
and severe anemia in the peripheral blood showed reticulin ﬁ  brosis 
and an increased number (average increase = 8%, 95% CI = 6% to 
10%,   P   < .001; the 10.9% increase in   Figure 1, E   is from one of 
ﬁ  ve separate experiments) of apoptotic cells compared with wild-
type mice (  Figure 1, D and E  ). The sick   Arid4a           /         mice (n > 50) 
also developed splenomegaly (  Figure 1, F  ) and hepatomegaly 
(  Figure 1, G  ) after 5 months of age, with extramedullary hemato-
poiesis in the spleen (  Figure 1, H  ) and liver (  Figure 1, I  ). A marked 
increase of erythropoiesis within enlarged spleens of the   Arid4a           /         
mice was demonstrated by ﬂ  ow cytometry analysis of spleen cells: 
65% of spleen cells were erythroid cells (Ter119        ) in mutants ver-
sus 7% in wild-type mice (difference = 58%, 95% CI = 53% to 
63%,   P   < .001) (  Figure 1, J  ). 
  In addition to their hematologic abnormalities, female 
  Arid4a           /         mice showed decreased fertility. Litter sizes for the 
  Arid4a         /       females mating with wild-type males were markedly lower 
than those for wild-type breeding pairs (0.7 vs 7.8, difference = 5.6, 
95% CI = 5.2 to 6.0.   P   < .001). Anemia, hepatosplenomegaly, and 
systemic illness may have contributed to the decreased fertility, but 
in addition there was hemorrhage into the ovarian follicles 
(Supplementary Figure 1, available online), as a result of profound 
thrombocytopenia (the mean platelet count in these mice was less 
than 100 × 10  6  /mL,   Figure 1, A  ). 
  Thus,   Arid4a           /         mice initially developed mild cytopenias with 
substantial thrombocytopenia and later progressed to monocytosis 
associated with more severe anemia and thrombocytopenia with 
spontaneous hemorrhage into organs (ie, ovary). Bone marrow 
failure with myeloﬁ  brosis was associated with hepatosplenomegaly 
due to compensatory extramedullary hematopoiesis. These abnor-
malities in the   Arid4a           /         mice suggest a myelodysplastic/myelopro-
liferative disorder and are similar to the course of events in humans 
with CMML derived from myelodysplastic/myeloproliferative 
diseases.   
    Development of AML in   Arid4a      —  /  —    Mice and 
  Arid4a      —  /  —     Arid4b   
    +  /   
  —    Mice 
  In patients with myelodysplastic/myeloproliferative diseases, pro-
gression to AML occurs with a frequency of 5%  –  30%. Similarly, 
we found that 5 of 42 (12%) of the   Arid4a           /         mice developed AML 
showing rapid and large increases of WBC counts with an onset 
between 12 and 22 months of age (data not shown). Hematologic 
malignancies were more frequent in the   Arid4a           /          Arid4b   
     /       mice. 
Of the 12   Arid4a           /          Arid4b   
     /       mice monitored beyond 5 months of 
age, 10 (83%) developed AML with an earlier age of onset (7  –  15 
months). 
      Neither the mice heterozygous for both Arid4a and Arid4b (n = 
36) nor wild-type controls (n = 52) developed AML over a 2-year 
period. littermates (data not shown). Postnatal growth was also de  -
layed (  Figure 2, A  ); body weight of   Arid4a           /          Arid4b   
     /       mice was 30% 
less than that of wild-type mice at 7 weeks of age (  Figure 2, B  ). 
The   Arid4a           /          Arid4b   
     /       mice also had increased postnatal mortal-
ity: 25% of mutant mice died before attaining 1 month of age 
(  Figure 2, C  ), and those that survived exhibited increased mortality 
at 7 months of age (  Figure 2, C  ) that was attributable to the 
increasing severity of their hematologic malignancies.         
  Bone marrow smears from mice with AML (two   Arid4a         /       mice 
and three   Arid4a         /        Arid4b   
     /       mice) demonstrated the presence of a 
mixture of immature and dysplastic WBC precursors with more than 
20% nonlymphoid immature forms and blasts (  Figure 3, A  ). Flow 
cytometric analysis of cell populations within the bone marrow 
from the   Arid4a           /         mice with CMML-like phenotype and the 
  Arid4a           /          Arid4b   
     /       mice with AML revealed that the majority 
of excess leukocytes were granulocytes and monocytes (22% of 
wild-type mice, 29% of mice with CMML-like phenotype, and 
63% of mice with AML were positive for Gr1 and Mac1, differ-
ence between wild-type and CMML-like mice = 7%,   P   = .124; 
difference between wild-type and AML mice = 41%,   P   = .002) 
(  Figure 4, A  ). This increase in granulocytes and monocytes was 
accompanied by an increase of T lymphoid cells (CD3        , 0.65% T 
lymphoid cells in wild-type mice, 3.16% in mice with CMML-like 
phenotype, and 5.99% in AML mice, difference between wild-type 
and CMML-like mice = 2.15%,   P   = .029; difference between wild-
type and AML mice = 5.34%,   P   < .001) and by decreases in B lym-
phoid cells (B220        CD19 
      , 9.4% in wild-type mice, 1.8% in mice jnci.oxfordjournals.org    JNCI | Articles 1251
      Figure 1    .        A chronic myelomonocytic leukemia (CMML)  –  like myelo-
dysplastic/myeloproliferative disorder in   Arid4a  -deﬁ   cient mice.   A  ) 
Complete blood counts (white blood cell, lymphocyte, neutrophil, mono-
cyte, red blood cell [RBC], hemoglobin, platelet) in wild-type mice at 2  –  5 
months of age (n = 35), in   Arid4a          /        mice at 2  –  5 months of age (n = 30), 
in wild-type mice more than 5 months old (n = 25), and in   Arid4a          /        mice 
more than 5 months old with symptoms of CMML (n = 25). Means (and 
95% conﬁ  dence intervals) for cell concentrations are shown, and   P   values 
were calculated using Student   t   test.   B  ) Wright  –  Giemsa staining of 
peripheral blood from an   Arid4a          /        mouse with symptoms of CMML, 
showing teardrop poikilocytes (a,   black arrowheads  ), red cells with 
Howell  –  Jolly bodies (b,   black arrowhead  ), and nucleated red cells (c, 
  black arrowhead  ). Immature (d,   white arrowhead  ) and maturing (d, 
  black arrowhead  ) mononuclear cells were also observed, together with 
phagocytosis of RBC by a monocyte (e,   arrowhead  ). Ten separate analy-
ses were performed.   Scale bars   = 5   µ  m.   C  ) Survival of   Arid4a          /        (n = 25) 
mice and wild-type (n = 25) mice.   D  ) Reticulin staining of parafﬁ  n sections 
of bone marrow from a wild-type mouse and a sick   Arid4a          /        mouse. The 
  Arid4a        /      sample shows ﬁ  brous tissue stained with black color. Scale 
bars = 20   µ  m.   E  ) Flow cytometric analysis of apoptotic cells in bone mar-
row from a wild-type and a sick   Arid4a          /        mouse. The percentages of cells 
positive for annexin V are indicated. Five separate cytometric analyses 
were performed.   F  ) Splenomegaly and   G  ) hepa  tomegaly in a sick 
  Arid4a          /        mouse. Hematoxylin and eosin  –  stained sections of   H  ) spleen 
and   I  ) liver from a wild-type mouse and a sick   Arid4a          /        mouse. 
Extramedullary hematopoiesis was found in the   Arid4a          /        spleen and 
  Arid4a          /        liver, which were inﬁ  ltrated with nucleated elements of blood 
cells. Ten separate analyses were performed. Scale bars = 20   µ  m.   J  ) Flow 
cytometric analysis of cells from spleen in a wild-type mouse and an 
  Arid4a        /      mouse stained with Ter119 surface antigen. The percentages of 
cells positive for the antigen are indicated. Twenty separate analyses 
were performed.       1252   Articles | JNCI  Vol. 100, Issue 17  |  September 3, 2008
with CMML-like phenotype, and 0.9% in AML mice, difference 
between wild-type and CMML-like mice = 7.6%,   P   < .001; differ-
ence between wild-type and AML mice = 8.5%,   P   < .001) and ery-
throid populations (Ter119        , 60% erythroid cells in wild-type 
mice, 54% in mice with CMML-like phenotype, and 36% in AML 
mice, difference between wild-type and CMML-like mice = 6%,   
P   = .378; difference between wild-type and AML mice = 24%,   
P   = .026) (  Figure 4, A  ).                 
  Examination of peripheral blood smears from the   Arid4a           /         and 
  Arid4a           /          Arid4b   
     /       mice with AML showed the presence of more 
than 20% of atypical cells with morphology consistent with blasts 
or immature myeloid precursors (  Figure 3, B  , a  –  d). There was 
accompanying monocytosis, and hemophagocytosis was often 
observed (  Figure 3, B, e  ). Serial monitoring of peripheral blood 
counts in mice developing AML revealed a rapid increase of WBC 
counts over a 2- to 4-week interval. The elevated WBC count was 
attributable to increased neutrophilic and monocytic forms (neu-
trophil: mean wild-type count = 0.75 × 10  6  /mL, mean AML count = 
8.50 × 10  6  /mL, difference = 7.75 × 10 
6  /mL, 95% CI = 5.85 × 10 
6  /mL 
to 9.65 × 10  6  /mL,   P   < .001; monocyte: mean wild-type count = 0.16 × 
10  6  /mL, mean AML count = 3.90 × 10 
6  /mL, difference = 3.74 × 
10  6  /mL, 95% CI = 2.54 × 10  6  /mL to 4.94 × 10  6  /mL,   P   < .001) 
(  Figure 4, A  ). Soon after the development of leukocytosis, the mice 
became moribund and were sacriﬁ  ced. In most of the   Arid4a           /     
     Arid4b         /       mice, AML occurred before development of severe ane-
mia (peripheral blood in   Figure 4, A  ; hemoglobin: mean wild-type 
count = 130 g/L, mean   Arid4a         /        Arid4b   
     /       count = 71 g/L, differ-
ence = 59 g/L, 95% CI = 40 g/L to 78 g/L,   P   < .001). Of the few 
  Arid4a           /         mice that progressed to AML, most developed a 
CMML-like phenotype and became moribund from severe anemia 
(hemoglobin: mean wild-type count = 130 g/L, mean   Arid4a         /       
count = 48 g/L, difference = 82 g/L, 95% CI = 76 g/L to 88 g/L, 
  P   < .001) (  Figures 1, A and 4, A  ).   
    Development of Myeloid Sarcoma in   Arid4a      —  /  —    and 
  Arid4a      —  /  —     Arid4b   
    +  /   
  —    Mice 
  In the human World Health Organization classification (  29  ), 
myeloid sarcoma is considered an alternative presentation of AML. 
The   Arid4a           /         mice and the   Arid4a   
       /          Arid4b   
     /       mice with leukemia 
also developed myeloid sarcoma. Soft tissue tumor nodules were 
found within the enlarged spleens (  Figure 5, A  ) and livers (  Figure 
5, B  ) that were infiltrated with aggressive leukemic (malignant) cells 
   
  Figure 2    .       Growth and survival of the   Arid4a   
    /       Arid4b   
    /      mice.   A  ) Growth retardation in an   Arid4a   
    /       Arid4b   
    /      mouse compared with a wild-type lit-
termate at 12 days of age.   B  ) Growth curve of the   Arid4a   
    /       Arid4b   
    /      (n = 7) and wild-type (n = 10) littermates by mean body weight plotted against 
age with 95% conﬁ  dence intervals.   C  ) Survival of   Arid4a   
    /       Arid4b   
    /      (n = 31) and wild-type (n = 25) mice.       
      Figure 3    .       Acute myeloid leukemia 
(AML)  –  like phenotype in   Arid4a   
    /  
     Arid4b        /      mice.   A  ) Bone marrow 
smears from a wild-type mouse and 
an   Arid4a        /       Arid4b   
    /      mouse with 
AML were stained with Wright  –
  Giemsa.   Black arrowheads   indicate 
blasts.   White arrowheads   indicate 
red blood cell precursors in both 
wild-type and AML bone marrow 
(for both wild-type and the  Arid4a   
    /    
  Arid4b   
    /      bone marrow smears, 
original magniﬁ   cations are the 
same). Five separate analyses were 
performed. Scale bars = 20   µ  m.   B  ) 
Wright  –  Giemsa staining of periph-
eral blood smears from the AML 
  Arid4a   
    /       Arid4b   
    /      mice showing 
blasts (a,   black arrowhead  ), lym-
phocytes (a,   white arrowhead  ), 
increased numbers of immature 
cells (b –  d,  arrowheads  ), and phago-
cytosis of cells by a macrophage 
(e). Eight separate analyses were 
performed. Scale bars = 5   µ  m.       jnci.oxfordjournals.org    JNCI | Articles 1253
      Figure 4    .        Hematopoietic lineage analysis of the   Arid4a        /      mice and 
  Arid4a   
    /       Arid4b   
    /      leukemic mice.   A  ) Comparison of cell populations in 
bone marrow and spleen (HSC, CMP, granulocyte, monocyte, erythroid 
cell, T cell, and B cell) and cell counts in peripheral blood (neutrophil, 
monocyte, hemoglobin, RBC, lymphocyte, and platelet) between wild-
type mice (n = 5), the   Arid4a   
    /      mice with CMML-like phenotype (n = 5), 
and the   Arid4a        /       Arid4b        /      mice with acute myeloid leukemia (AML) (n = 5). 
Means (and 95% conﬁ  dence intervals) for all cell populations and cell 
counts are shown, and   P   values were calculated using Student   t   test. 
  B  ) Hematopoietic lineage tree displaying the combined impact of the   Arid4a   
mutation with or without the   Arid4b   mutations in bone marrow and 
peripheral blood of mice with CMML-like or AML phenotype. Increased 
and decreased cell populations are indicated by   red   and   green  , respec-
tively. HSC, hematopoietc stem cell; CMP, common myeloid progenitor; 
CLP, common lymphoid progenitor; GMP, granulocyte and monocyte 
progenitor; MkP, megakaryocyte progenitor; EP, erythroid progenitor.       1254   Articles | JNCI  Vol. 100, Issue 17  |  September 3, 2008
(  Figure 5, C  ). Blood vessels in the lungs of the AML mice showed 
a marked increase of nucleated elements, indicative of leukemic 
involvement (  Figure 5, D  ). Similar lesions composed of leukemic 
cells were also found in lymph nodes and kidneys (data not shown). 
Flow cytometric analysis of cell populations within the splenic tis-
sue showed an increase of leukocytes of granulocytic and monocytic 
origin (Gr1         and Mac1 
      , 3% in wild-type mice, 13% in mice with 
CMML-like phenotype, and 26% in AML mice, difference 
between wild-type and CMML-like mice = 10%,   P   < .001; differ-
ence between wild-type and AML mice = 23%,   P   < .001) (  Figure 4, A  ). 
This increase in granulocytes and monocytes was accompanied 
by an increase of erythroid cells (Ter119        , 6% erythroid cells in 
wild-type mice, 63% in mice with CMML-like phenotype, and 
54% in AML mice, difference between wild-type and CMML-like 
mice = 57%,   P   < .001; difference between wild-type and AML mice = 
48%,   P   < .001) and relative decreases of the T lymphoid (CD3        , 
26.7% in wild-type mice, 5.5% in mice with CMML-like pheno-
type, and 7.6% in AML mice, difference between wild-type and 
CMML-like mice = 21.2%,   P   < .001; difference between wild-type 
and AML mice = 19.1%,   P   < .001) and B lymphoid (B220        CD19 
      , 
58.9% in wild-type mice, 4.8% in mice with CMML-like pheno-
type, and 6.7% in AML mice, difference between wild-type and 
CMML-like mice = 54.1%,   P   < .001; difference between wild-type 
and AML mice = 52.2%,   P   < .001) populations (  Figure 4, A  ). These 
features fulfill the criteria for AML (granulocytic and monocytic) 
and myeloid (granulocytic) sarcoma in mice (Bethesda proposals) 
(  30  ).           
    Expansion of HSCs and Downstream Progenitors in 
  Arid4a      —  /  —    and   Arid4a   
  —  /  —     Arid4b     
  +  /   
  —    Mice 
  Because the abnormalities were found in all hematologic lineages, 
we tested whether deficiency of   Arid4a   and   Arid4b   has effects on 
HSCs and downstream progenitors. Compared with wild-type 
mice,   Arid4a           /         mice had an increased proportion of HSCs 
(Lin        Sca1 
      c-Kit 
      , referred to as L 
      S 
      K 
      , 0.24% in wild-type mice, 
0.40% in   Arid4a           /         mice, difference = 0.16%,   P   = .041) in bone 
marrow (  Figure 4, A  ). In mice that were also heterozygous for the 
  Arid4b   mutation, there was greater expansion of the HSCs 
      Figure 5    .       Development of myeloid sarcoma in   Arid4a   
      /         Arid4b   
    /      mice. 
  A  ) Splenomegaly and   B  ) hepatomegaly in the acute myeloid leukemia 
(AML)   Arid4a   
    /       Arid4b   
    /      mice relative to spleen and liver from wild-
type littermates.   C  ) Histologic analysis of spleen and liver from a 
wild-type mouse and an AML   Arid4a   
    /       Arid4b   
    /      mouse. Parafﬁ  n sec-
tions were stained with hematoxylin and eosin.   Black arrowheads   
indicate mitotic leukemic cells in spleen and liver from the   Arid4a   
    /      
Arid4b   
    /      mouse.   White arrowheads   indicate hepatocytes.   D  ) His-
tologic analysis of lungs from a wild-type and an   Arid4a   
    /      mouse. 
Parafﬁ   n sections were stained with hematoxylin and eosin. Blood 
vessels in the   Arid4a   
    /      lungs showed a marked increase of leukemic 
cells.       jnci.oxfordjournals.org    JNCI | Articles 1255
population in the   Arid4a   
       /          Arid4b   
     /       bone marrow (L 
      S 
      K 
      , 0.24% 
in wild-type mice, 0.55% in   Arid4a           /          Arid4b   
     /       mice, difference = 
0.31%,   P   < .001) (  Figure 4, A  ). Furthermore, the proportions of 
CMPs (Lin        Sca1 
      c-Kit 
      , referred as L 
      S 
      K 
      ) in the   Arid4a   
       /         and 
  Arid4a           /          Arid4b   
     /       bone marrow were statistically significantly 
higher than those from wild-type mice (L        S 
      K 
      , 0.4% in wild-type 
mice, 2.0% in mice with CMML-like phenotype, and 2.1% in 
AML mice, difference between wild-type and CMML-like mice = 
1.6%,   P   < .001; difference between wild-type and AML mice = 1.7%, 
  P   < .001) (  Figure 4, A  ). In the spleen, dramatic increases of the HSC 
(L        S 
      K 
      , 0.03% in wild-type mice, 0.4% in mice with CMML-like 
phenotype, and 0.55% in AML mice, difference between wild-type 
and CMML-like mice = 0.37%,   P   = .02; difference between wild-
type and AML mice = 0.52%,   P   = .004) and CMP (L        S 
      K 
      , 0.01% 
in wild-type mice, 5.13% in mice with CMML-like phenotype, and 
5.01% in AML mice, difference between wild-type and CMML-
like mice = 5.12%,   P   = .028; difference between wild-type and AML 
mice = 5%,   P   = .014) populations were found in both   Arid4a           /         
mice and   Arid4a           /          Arid4b   
     /       mice (  Figure 4, A  ), suggesting that 
extramedullary hematopoiesis in spleen might be due to mobiliza-
tion of HSCs from bone marrow. 
  Collectively, our data suggested the following disease model for 
the observed hematologic disorders. Deﬁ   ciency of   Arid4a   and 
  Arid4b   results in increase of HSCs, CMPs, and Gr1        Mac1 
       
myeloid cells in bone marrow and spleen, which leads to increases 
of neutrophils and monocytes in the peripheral blood (  Figure 4, B  ). 
Despite the compensatory erythropoiesis within the enlarged 
spleen due to the decrease of erythroid activity in the bone marrow 
(  Figures 1, J and 4, A and B  ), the enlarged spleen sequestrates 
RBCs. Although it is not known if the reduction in platelets is due 
to decreased production or increased destruction, the reduction 
leads to spontaneous hemorrhage (Supplementary Figure 1, avail-
able online). All of these processes contribute to a decrease of 
RBCs in peripheral blood (  Figure 4, B  ). Although the proportion 
of T lymphoid cells was increased in the bone marrow, the popula-
tion of B lymphoid cells was substantially decreased, leading to the 
lower number of total lymphocytes in the peripheral blood (  Figure 
4, B  ). Thus,   Arid4a   and   Arid4b   have essential roles in hematopoi-
etic homeostasis and in lineage fate determination.   
    Disturbed Patterns of Histone Modifications in   Arid4a      —  /  —    
Bone Marrow Cells 
  The ARID4A and ARID4B proteins contain a chromodomain and 
a Tudor domain. Both domains have been reported to mediate 
binding to methylated lysines of histones H3 and H4 (  11    –    14  ). 
Given the bone marrow failure phenotype found in the   Arid4a           /         
mice, we investigated the expression and methylation status of his-
tones in bone marrow of these mice. By western blot analysis, levels 
of histones H3 and H4 were elevated by 2.7- and 2.2-fold, respec-
tively (95% CI = 2.3 to 3.1 and 1.9 to 2.5, respectively) in the 
  Arid4a           /         bone marrow constituents compared with the wild-type 
samples (  Figure 6, A  ). Levels of H2AX were not different. 
Methylation of lysine in H3 can lead to either repression or activa-
tion of gene expression; trimethylation of H3K4 (H3K4me3) is 
associated with transcriptional activation at euchromatic regions, 
whereas trimethylation of H3K9 (H3K9me3) is usually associated 
with repressive states at pericentric heterochromatin. Analysis of 
H3 lysine methylation revealed very large increases of both 
H3K4me3 (32-fold, 95% CI = 27 to 37) and H3K9me3 (45-fold, 
95% CI = 41 to 49) in the bone marrow cells from the   Arid4a           /         
mice compared with wild-type mice (  Figure 6, A  ). As detected by 
immunofluorescence, H3K4me3 was broadly distributed over 
euchromatic regions but showed speckled patterns in both wild-
type and   Arid4a           /         bone marrow cells (  Figure 6, B  ). In wild-type 
bone marrow cells, H3K9me3 was localized in discrete spots in the 
DAPI-dense regions that correspond to the pericentric heterochro-
matin structure (  Figure 6, B  ).   Arid4a           /         bone marrow cells showed 
a diffuse pattern of H3K9me3-derived immunofluorescence 
with small foci spread throughout the nuclei (  Figure 6, B  ). These 
different patterns of H3K9me3 between wild-type and the 
  Arid4a           /         samples were obvious across the great majority of cells in 
the marrow even though the cell populations in wild-type and the 
  Arid4a           /         bone marrow samples were different (  Figure 4, A  ). These 
differences of immunofluorescence staining patterns of H3K9me3 
were not seen in primary mouse embryo fibroblasts (pMEFs) 
(  Figure 6, B  ). Trimethylation of H4K20 (H4K20me3) is another 
modification usually found on repressed chromatin accumulated at 
pericentric heterochromatin regions. When analyzed by western 
blotting, the   Arid4a           /         bone marrow cells revealed a slight increase 
of H4K20me3 (2.2-fold, 95% CI = 1.7 to 2.7), which might reflect 
increased expression of histone H4 (2.2-fold, 95% CI = 1.9 to 2.5) 
(  Figure 6, A  ). The fluorescence signals representing H4K20me3 
were focally enriched at pericentric heterochromatin in both wild-
type and the   Arid4a           /         bone marrow cells (  Figure 6, B  ). Collectively, 
these re    sults suggest that   Arid4a   participates in regulating lysine 
trimethylation of histones H3 and H4 in bone marrow.           
    Decreased Expression of the   Hox   and   Fox   Genes in Bone 
Marrow Cells with   Arid4a   and   Arid4b        + /  —    Mutations 
  To investigate the downstream genes regulated by   Arid4a   and 
  Arid4b  , we first compared gene expression of wild-type pMEFs and 
  Arid4a           /          Arid4b   
     /       pMEFs using gene expression microarrays. We 
identified genotype-specific differences in expression of   Hox   and 
  Fox   genes (data not shown). To further elucidate the regulatory 
mechanisms by which   Arid4a   and   Arid4b   are involved in acquisition 
of the leukemic phenotype, we compared expression of several 
genes important for normal hematopoiesis and leukemogenesis. 
These included the homeobox genes in the   Hox   clusters (  Hoxa  , 
  Hoxb  , and   Hoxc  ) (  31  ,  32  ), homeodomain transcription factors   Pbx1   
(  33  ),   Meis1   (  34  ), and   Pitx2   (  35  ),   AML1   (acute myeloid leukemia 1) 
(  36  ),   Mll   (mixed-lineage leukemia) (  37  ), and the forkhead box gene 
  Foxp3   (  38  ,  39  ). We compared the expression of these genes in bone 
marrow from wild-type,   Arid4a           /        , and   Arid4a   
       /          Arid4b   
     /       mice. 
To minimize variation arising from differences in cell populations, 
we collected bone marrow cells from mice before development of 
illness. We monitored relative gene expression levels using reverse 
transcription  –  PCR. The expression of several   Hoxb   genes, includ-
ing   Hoxb3  ,   Hoxb5  ,   Hoxb6  , and   Hoxb8  , but not   Hoxb4  , was decreased 
in both   Arid4a           /         and   Arid4a   
       /          Arid4b   
     /       bone marrow compared to 
wild-type mice. This decrease was specific for   Hoxb   genes because 
the expression of   Hoxa  7,   Hoxa9  ,   Hoxc6  ,   Pbx1  , and   Meis1   was not 
altered (  Figure 7, A  ). The expression of   Pitx2   that is required for 
normal hematopoiesis was also reduced in   Arid4a           /         and   Arid4a   
       /     
     Arid4b   
     /       bone marrow (  Figure 7, A  ). In contrast, expression of 1256   Articles | JNCI  Vol. 100, Issue 17  |  September 3, 2008
  AML1   and   Mll  , genes involved in leukemogenesis, was similar in all 
the bone marrow samples (  Figure 7, A  ). These results suggested 
that   Arid4a   regulates hematopoiesis by controlling the expression 
of specific homeodomain genes, such as   Pitx2   and a subset of   Hoxb   
genes.         
  The FOXP3 protein plays an important role in control of the 
regulatory T-cell lineage (  40  ), and   Foxp3   was recently identiﬁ  ed as 
a tumor suppressor gene (  41  ). The expression of   Foxp3   was reduced 
speciﬁ  cally in the   Arid4a           /          Arid4b   
     /       bone marrow but not in the 
  Arid4a           /         bone marrow (  Figure 7, A  ), suggesting that downregula-
tion of   Foxp3   may be involved in the mechanisms underlying the 
increased numbers of T cells in the   Arid4a           /          Arid4b   
     /       bone marrow 
(  Figure 4, A  ) and the high frequency of leukemia malignancies in 
the   Arid4a           /          Arid4b   
     /       mice.     
    Discussion 
    Arid4a   and   Arid4b   knockout mice provide a suitable animal model 
for better understanding the progression of a premalignant hema-
tologic disorder and the eventual transformation to AML. Using 
this model, we found disruption of myeloid homeostasis in the 
  Arid4a         /       mice due to the increase of HSCs and downstream pro-
genitors, which might be the principal components of the expan-
sion of a transformed leukemic stem cell compartment with 
aggressive self-renewal properties. We have obtained some 
insight into the molecular mechanisms by defining the down-
stream regulatory impact on the   Hox   and   Fox   genes. Moreover, 
our results suggest that   Arid4a   controls chromatin modification 
necessary to support normal hematopoiesis, and the data are con-
sistent with an important role of epigenetic regulation in cancer 
development. 
  H3K4me3 is a mark of transcriptionally active chromatin states, 
whereas the H3K9me3 and H4K20me3 modiﬁ  cations are usually 
found at repressive chromatin domains. However, we found that 
H3K4me3, H3K9me3, and H4K20me3 were all increased in bone 
marrow cells from mice deleted for   Arid4a  . We envision that these 
histone methylations will reach a combinatorial steady state that 
may mediate activation or repression of speciﬁ  c genomic loci or 
chromosome domains. We propose that ARID4A is a critical 
determinant for distinct histone methylation states and that it plays 
   
  Figure 6    .       Histone modiﬁ  cations in bone marrow cells of mice lacking 
  Arid4a  .   A  ) Western blot analysis of acid-extracted proteins from bone 
marrow of a wild-type and an   Arid4a   
      /        mouse. Total proteins were trans-
ferred to a nitrocellulose membrane and stained with Ponceau S (top), 
followed by staining with antibodies against histones H3, H4, H2AX, 
H3K4me3, H3K9me3, and H4K20me3 (bottom). Ratios of histones were 
quantiﬁ  ed by densitometry. Five separate experiments were performed. 
  B  ) Immunoﬂ  uorescence analysis of bone marrow cells or primary mouse 
embryo ﬁ  broblasts from wild-type and the   Arid4a   
    /      mice using antibod-
ies against H3K4me3, H3K9me3, and H4K20me3. DNA was counter-
stained with DAPI. Images were analyzed by deconvolution microscopy. 
Three separate experiments were performed, all with similar results.       jnci.oxfordjournals.org    JNCI | Articles 1257
an important role in coordination between the modiﬁ  cation marks 
at different chromatin regions. Further analysis of chromatin-
speciﬁ   c components associated with ARID4A and/or ARID4B 
could more clearly address the contribution of these two proteins 
to the combinatorial pattern of histone modiﬁ  cations. A goal of 
future research should be to determine whether ARID4A and 
ARID4B contain any intrinsic enzyme activity and whether they 
mediate their effects either through direct interaction with chro-
matin complexes or through intermediate steps involving various 
pathways that are modulated through chromatin remodeling. 
  Our results suggest plausible molecular mechanisms for the 
hematologic disorder in   Arid4a  -deﬁ  cient mice based on downregu-
lation of a number of homeobox genes (  Pitx2   and a cluster of   Hoxb   
genes including   Hoxb3  ,   Hoxb5  ,   Hoxb6  , and   Hoxb8  ) in   Arid4a         /       bone 
marrow cells with or without   Arid4b   haploinsufﬁ  ciency. A homeo-
box sequence encodes a protein domain that binds DNA. Homeobox 
genes encode transcription factors and are classiﬁ  ed into two sub-
groups: Hox and non  –  Hox genes. Abnormal expression of both 
groups of homeobox genes plays a role in the pathogenesis of 
myeloid malignancies (  31  ,  32  ). Little is known about the molecular 
mechanisms of homeobox gene regulation, but the   MLL   gene is 
reported to positively regulate multiple   Hox   genes (  28  ).   MLL   
encodes a histone methyltransferase that methylates H3K4 (  42  ). 
Leukemogenic   MLL   translocations deﬁ  ne a speciﬁ  c group of leuke-
mias (mixed lineage leukemia) (  43  ). We suggest that   Arid4a   and 
  Arid4b   play a prominent role in leukemic transformation by control-
ling the trimethylation of H3K4 and H3K9. Although we did not 
ﬁ  nd that mutations of   Arid4a   and   Arid4b   affected the expression of 
  Mll  , our results suggest plausible molecular mechanisms whereby 
  Arid4a   and   Arid4b   might regulate hematopoiesis by controlling the 
expression of speciﬁ  c homeodomain genes, such as   Pitx2  , required 
for normal erythropoiesis (  44  ), and a subset of   Hoxb   genes, including 
  Hoxb6  , whose disruption results in an increase of early erythrocyte 
progenitors (  45  );   Hoxb  8, which affects lineage-speciﬁ  c development 
of hematopoietic progenitor cells (  46  ,  47  ); and   Hoxb3  , whose deﬁ  -
ciency impairs B lymphopoiesis (  48  ) (  Figure 7, B  ). 
  Our results also imply that   Arid4a   and   Arid4b   are involved in the 
regulation of a forkhead box gene   Foxp3   (  Figure 7, B  ), an X chromo-
some  –  encoded forkhead transcription factor family member that 
plays an important role in the development and function of natural 
regulatory T cells (  40  ). FOXP3 protein interacts with AML1 to con-
trol regulatory T-cell function (  39  ). Although   Arid4a   and   Arid4b   
mutations did not affect the expression of   AML1  , we found decreased 
expression of   Foxp3   in the   Arid4a           /          Arid4b   
     /       mice. FOXP3 functions 
as a transcriptional regulator by assembling chromatin remodeling 
complexes involved in histone modiﬁ  cation (  49  ). In humans, muta-
tions of   FOXP3   leads to an X-linked fatal autoimmune disease known 
as IPEX (immune dysregulation, polyendocrinopathy, enteropathy, 
X-linked) syndrome and an analogous lymphoproliferative disease 
(  50  ). Deﬁ  ciency of   Foxp3   in mice leads to an early onset, highly 
aggressive and fatal autoimmune disease characterized by excessive 
proliferation of CD4         T cells and extensive inﬁ  ltration by leukocytes 
in multiple organs (  38  ,  51  ,  52  ). Recently, it has been reported that 
FOXP3 protein functions as a tumor suppressor involved in the devel-
opment of breast cancer (  41  ). Decreased expression of   Foxp3   may be 
involved  in the disease mechanisms through epigenetic effects in the 
  Arid4a           /          Arid4b   
     /       mice, which develop an increased population of T 
cells in bone marrow and progress to AML and myeloid sarcoma with 
various tissues inﬁ  ltrated by leukemic cells. It will be of interest to 
examine whether decreased expression of   Foxp3   contributes to the 
high frequency of leukemia malignancies in the   Arid4a           /          Arid4b   
     /       
mice. 
  We present evidence that ARID4A and ARID4B function as 
tumor suppressors and that a myelodysplastic/myeloproliferative       
disorder in mice carrying the   Arid4a   or/and   Arid4b   mutations pro-
gresses to hematologic malignancies, resembling human CMML 
and AML. However, we have not investigated whether mutations 
in   ARID4A   and   ARID4B   participate in genetic and/or epigenetic 
mechanisms of human CMML and AML, or other cancers. 
Although the ARID4A and ARID4B proteins have been identiﬁ  ed 
as breast cancer  –  associated antigens (  3  ,  20  ,  21  ) and   Arid4a   and 
  Arid4b   are involved in the regulation of   Foxp3  , which functions as 
a breast cancer suppressor gene (  41  ), we have not observed primary 
solid tumors in mice with ARID4 family deﬁ  ciency, (although we 
have not performed a detailed search for breast cancer). Further 
study of the   Arid4   gene family may advance our understanding of 
the connection between gene regulation, epigenetic control, 
   
  Figure 7    .       Gene expression analysis of bone marrow cells from wild-
type,   Arid4a   
    /     , and   Arid4a   
    /       Arid4b   
    /      mice.   A  ) Reverse transcriptase  –
  polymerase chain reaction was performed to analyze the genes 
indicated, with   Hprt   serving as the control gene. Three separate experi-
ments were performed.   B  ) Pathways by which   Arid4a   and   Arid4b   might 
regulate hematopoiesis through control of the   Hox   and   Fox   genes. In 
the scenario shown,   Arid4a   controls erythropoiesis, possibly by posi-
tively regulating   Pitx2   and   Hoxb6   genes.   Arid4a   also controls the 
expression of   Hoxb8  , whose product blocks differentiation of hemato-
poietic stem cells and common myeloid progenitors. Control of B lym-
phopoiesis by   Arid4a   may be achieved by increasing expression of 
  Hoxb3  .   Arid4a  , together with   Arid4b  , increases expression of   Foxp3  , 
which acts on regulatory T (TR) cells to suppress conventional T (Tc) 
cells.   Foxp3   also functions as a tumor suppressor gene. However, it is 
unclear whether   Foxp3   suppresses leukemia malignancies.       1258   Articles | JNCI  Vol. 100, Issue 17  |  September 3, 2008
disease development, and cancer formation. We also suggest that 
gene regulation by ARID4A and ARID4B should be examined for 
potential disease-related roles, not only in human malignancies, 
but also in other complex disease traits.         
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